Symbiotix Biotherapies Inc is categorized under Commercial Biotechnical Research in Brookline, MA and active since 2009.
Symbiotix Biotherapies Inc was established in 2009, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Nader Yaghoubi at the company’s single location by writing to 15 Hyslop Road, Brookline, Massachusetts MA 02445 or by phoning (617) 968-3006. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Symbiotix Biotherapies Inc |
| Contact Person: | Nader Yaghoubi |
| Address: | 15 Hyslop Road, Brookline, Massachusetts 02445 |
| Phone Number: | (617) 968-3006 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2009 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Symbiotix Biotherapies Inc was started in 2009 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Nader Yaghoubi for inquiries that concern Symbiotix Biotherapies Inc by calling the company number (617) 968-3006, as your correspondence is most welcome. Additionally, the physical location of the single location of Symbiotix Biotherapies Inc can be found at the coordinates 42.331889,-71.140522 as well as the street address 15 Hyslop Road in Brookline, Massachusetts 02445.
For its online presence, you may visit Symbiotix Biotherapies Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.